175.10

3.07% -5.54

After Hours: 175.50 0.40 +0.23%

Beigene Ltd Adr (ONC)

Overview News Price History Discussions Forecast

Beigene Ltd Adr stock is traded at $175.10, with a volume of 354.34K. It is down -3.07% in the last 24 hours and up +0.00% over the past month. Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.

Previous Close:

$180.64

Open:

$176.11

24h Volume:

354.34K

Relative Volume:

27.55

Market Cap:

$18.65B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+0.00%

1M Performance:

+0.00%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$175.00

$180.40

1-Week Range:

$175.00

$184.76

52-Week Range:

$175.00

$184.76

Beigene Ltd Adr Stock (ONC) Company Profile

Name

Beigene Ltd Adr

Sector

Healthcare (1174)

Industry

Biotechnology (671)

Phone

13459494123

Address

C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN

Employee

10,000

Twitter

Next Earnings Date

Latest SEC Filings

ONC's Discussions on Twitter

Compare ONC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ONC Beigene Ltd Adr	175.10	18.65B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	408.32	105.15B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	730.30	80.25B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	648.62	38.79B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	235.95	30.43B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	126.88	30.42B	3.30B	-501.07M	1.03B	-2.1146

Beigene Ltd Adr Stock (ONC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-03-24	Resumed	Morgan Stanley	Overweight
Sep-18-24	Initiated	JMP Securities	Mkt Outperform
Feb-06-24	Resumed	JP Morgan	Overweight
Sep-12-23	Initiated	Macquarie	Outperform
Aug-17-23	Initiated	Jefferies	Buy
Jul-17-23	Initiated	Citigroup	Buy
Jun-30-23	Downgrade	Bernstein	Outperform → Mkt Perform
Jan-12-23	Initiated	Daiwa Securities	Buy
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy
Oct-13-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Aug-09-22	Resumed	JP Morgan	Overweight
Mar-17-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Feb-07-22	Initiated	Deutsche Bank	Buy
Oct-12-21	Initiated	Bernstein	Outperform
Oct-06-21	Upgrade	CLSA	Underperform → Buy
Mar-08-21	Initiated	China Renaissance	Buy
Mar-01-21	Downgrade	CLSA	Outperform → Underperform
Nov-09-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Nov-06-20	Downgrade	Maxim Group	Buy → Hold
Nov-06-20	Downgrade	Piper Sandler	Neutral → Underweight